San Francisco, California – Immumem Therapeutics, a biotechnology company pioneering next-generation cell therapies for refractory solid tumors, today announced it has secured backing from LvlUp Ventures’ LvlUp Labs- a non-equity startup program. The funding and strategic support will accelerate Immumem’s mission to rebuild the foundational infrastructure of oncology treatments by combining allogeneic iPSC-derived memory T and NK (T/NK) cells with proprietary predictive AI.
LvlUp Ventures, known for identifying founders operating at the intersection of technical depth, execution speed, and real market demand, highlighted Immumem Therapeutics in their latest fund update. The venture firm emphasized Immumem’s unique capability to address one of the most difficult challenges in oncology today: the high rate of relapse in solid tumors.
“Biotech remains one of the most difficult sectors to build in, but also one of the most impactful,” LvlUp Ventures noted in their official announcement. “Immumem Therapeutics is developing next-generation memory cell therapies designed to address one of oncology’s biggest challenges: relapse in solid tumors. The combination of scientific rigor and operational execution gives us strong conviction in the direction they are building toward.”
Unlike traditional therapies that fail to penetrate the immunosuppressive tumor microenvironment (TME), Immumem’s multiplex-edited TNK therapies feature over 10 precise gene edits delivering 15 functional capabilities, including exhaustion resistance and enhanced solid tumor infiltration. These therapies are designed not only to attack tumors but to continuously monitor and prevent recurrence over time.
“We are executing at the pace of a fully funded, institutional-grade biotech team, and LvlUp Ventures immediately recognized that outlier velocity,” said Shubh Gupta, PhD, CEO/CSO and Founder of Immumem Therapeutics. “While our competitors burn millions of dollars on trial-and-error animal models, our VIVO-IQ predictive AI engine computationally de-risks our assets with over 90% clinical accuracy before we ever deploy capital in vivo. This backing from LvlUp Ventures perfectly aligns with our capital-efficient model and accelerates our strict 36-month timeline to IND readiness.”
In their investment thesis, LvlUp Ventures pointed to several early traction signals that separated Immumem from its well-funded competitors, including superior in vivo efficacy compared to benchmark therapies and unmatched computational efficiency in predicting clinical efficacy.
The backing from LvlUp Ventures serves as a massive validation of Immumem’s dual-moat approach – deep biological engineering paired with extreme computational capital efficiency – positioning the company to lead the next wave of biotech innovation.
About Immumem Therapeutics
Immumem Therapeutics is a San Francisco-based biotechnology company targeting refractory solid tumors with very low remission rates. By engineering off-the-shelf, multiplex-edited iPSC-derived TNK cell therapies, Immumem actively dismantles the immunosuppressive tumor microenvironment to eliminate cancer relapse. Powered by the VIVO-IQ predictive AI engine, the company operates with unprecedented capital efficiency, computationally de-risking clinical efficacy to accelerate its path to the clinic.
Media Contact:
Immumem Therapeutics Corp
Email: contact@immumemtx.com